John Shannon - Xeris Pharmaceuticals President COO
| XERS Stock | USD 3.35 0.19 5.37% |
President
Mr. John Shannon is a Chief Operating Officer of the Company. Shannon has 30 years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, operations and manufacturing, strategic planning and business development. Most recently, Mr. Shannon spent 2 years as Chief Executive Officer for Catheter Connections, Inc.. CCI developed and commercialized innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Its DualCap System is a family of userfriendly products that provides healthcare facilities with a costeffective, integrated solution for IV disinfection and protection, helping in the fight against IV catheterrelated blood stream infections. CCI was acquired by Merit Medical in January of 2016. Prior to CCI, Mr. Shannon spent 3 years as Chief Commercial Officer for Durata Therapeutics. Durata Therapeutics was an innovative new pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions to advance patient care in infectious disease and acute illnesses. Durata was acquired by Actavis for 675 million, December 2014. Prior to that, Mr. Shannon spent 10 years at Baxter Healthcare where he was General Manager, Global Hemophilia and Global Commercial Excellence, General Manager, US Biopharmaceuticals, Vice President Marketing US Bioscience and Vice President Marketing US Renal. During his time at Baxter he led the commercialization and drove the growth of two Baxter brands, Advate and Gammagard, both which now exceed billion dollars each. Prior to coming to Baxter, he was Vice President, Marketing for Caremark. Before that he was at Searle for 10 years where he held several positions most importantly, Executive Director, Cardiovascular Global Commercialization, responsible for the commercial development and marketing of new cardiovascular products worldwide and the Sr since 2017.
| Age | 63 |
| Tenure | 8 years |
| Address | 180 North LaSalle Street, Chicago, IL, United States, 60601 |
| Phone | 844 445 5704 |
| Web | https://www.xerispharma.com |
John Shannon Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Shannon against Xeris Pharmaceuticals stock is an integral part of due diligence when investing in Xeris Pharmaceuticals. John Shannon insider activity provides valuable insight into whether Xeris Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Xeris Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Xeris Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Shannon over a month ago Disposition of 15692 shares by John Shannon of Xeris Pharmaceuticals at 2.11 subject to Rule 16b-3 | ||
John Shannon over six months ago Acquisition by John Shannon of 750000 shares of Xeris Pharmaceuticals subject to Rule 16b-3 | ||
John Shannon over a year ago Acquisition by John Shannon of 34977 shares of Xeris Pharmaceuticals subject to Rule 16b-3 |
Xeris Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.087) % which means that it has lost $0.087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 8.67 in 2025, whereas Return On Tangible Assets are likely to drop (0.31) in 2025. At this time, Xeris Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 5.5 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (84 M).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Atul Saran | Emergent Biosolutions | 51 | |
| Gianfranco Nazzi | Teva Pharma Industries | 50 | |
| Sven Dethlefs | Teva Pharma Industries | 55 | |
| Eliyahu Kalif | Teva Pharma Industries | 52 | |
| Michael Olchaskey | Intracellular Th | N/A | |
| Kathleen Veit | Teva Pharma Industries | N/A | |
| David Stark | Teva Pharma Industries | 55 | |
| Andrew Plump | Takeda Pharmaceutical Co | 59 | |
| Masato Iwasaki | Takeda Pharmaceutical Co | 61 | |
| Richard Daniell | Teva Pharma Industries | 58 | |
| Robert Kramer | Emergent Biosolutions | 62 | |
| Richard Lindahl | Emergent Biosolutions | 60 | |
| Keith Choy | Haleon plc | 56 | |
| Mark Neumann | Intracellular Th | 62 | |
| John Condon | Intracellular Th | N/A | |
| Filippo Lanzi | Haleon plc | N/A | |
| John Bardi | Intracellular Th | N/A | |
| Mark Sabag | Teva Pharma Industries | 54 | |
| Giles Platford | Takeda Pharmaceutical Co | 46 | |
| Lisa Paley | Haleon plc | 58 | |
| Christina Ackermann | Bausch Health Companies | 55 | |
Management Performance
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 |
Xeris Pharmaceuticals Leadership Team
Elected by the shareholders, the Xeris Pharmaceuticals' board of directors comprises two types of representatives: Xeris Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xeris. The board's role is to monitor Xeris Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xeris Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xeris Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Senior Affairs | ||
| Beth JD, Chief Secretary | ||
| Steven Pieper, Chief Officer | ||
| Dr MBA, CoFounder Officer | ||
| Paul Edick, President CEO, Director | ||
| John Shannon, President COO | ||
| Paul JD, Senior Advisor | ||
| Kevin McCulloch, Chief Officer | ||
| Kendal Korte, Senior Resources | ||
| Brian Conner, SVP Officer | ||
| Allison Wey, Senior Communications |
Xeris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xeris Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.17 | ||||
| Return On Asset | -0.087 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 729.31 M | ||||
| Shares Outstanding | 149.08 M | ||||
| Shares Owned By Insiders | 3.92 % | ||||
| Shares Owned By Institutions | 43.96 % | ||||
| Number Of Shares Shorted | 9.52 M | ||||
| Price To Book | 3.34 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.